These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 11214235)

  • 1. Physicochemical characterisation of the pertussis vaccine.
    Ceccarini C; Contorni M; Costantino P; D'Ascenzi S; Gallo E; Maffei M; Mannucci D; Marsili I; Magagnoli C; Peppoloni S; Rappuoli R; Ravenscroft N; Ricci S
    Dev Biol (Basel); 2000; 103():175-88. PubMed ID: 11214235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The preparation of A purified immunogenic pertactin from B. pertussis.
    El-Kady EM; Abu-Shady HM; Tohamy HS; Wahby AF
    Egypt J Immunol; 2007; 14(2):11-8. PubMed ID: 20306653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The reaction of bacterial toxins with formaldehyde and its use for antigen stabilization.
    Petre J; Pizza M; Nencioni L; Podda A; De Magistris MT; Rappuoli R
    Dev Biol Stand; 1996; 87():125-34. PubMed ID: 8854009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cellular and acellular anti-pertussis vaccines].
    Locht C
    Ann Pharm Fr; 2001 May; 59(3):198-205. PubMed ID: 11427821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and clinical testing of an acellular pertussis vaccine containing genetically detoxified pertussis toxin.
    Rappuoli R; Pizza M; De Magistris MT; Podda A; Bugnoli M; Manetti R; Nencioni L
    Immunobiology; 1992 Feb; 184(2-3):230-9. PubMed ID: 1587545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Purification design and practice for pertactin, the third component of acellular pertussis vaccine, from Bordetella pertussis.
    Li Z; Zhang Y; Wang Q; Li Z; Liu Y; Zhang S; Zhang G; Ma G; Luo J; Su Z
    Vaccine; 2016 Jul; 34(34):4032-9. PubMed ID: 27302339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineering bacterial toxin for the development of new vaccine against pertussis.
    Bartoloni A; Pizza M; Gross R; Perugini M; Arico B; Domenighini M; Rappuoli R
    Tokai J Exp Clin Med; 1988; 13 Suppl():217-22. PubMed ID: 2483870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the protective effects of the pertussis acellular vaccine with the component vaccine, which have different amounts of fimbriae, against the experimental aerosol infection of mice with Bordetella pertussis.
    Morokuma K; Ginnaga A; Nishihara T; Tsunoda S; Furukawa M; Aihara K; Sakoh M
    Dev Biol Stand; 1991; 73():223-32. PubMed ID: 1685713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outer membrane vesicles as acellular vaccine against pertussis.
    Roberts R; Moreno G; Bottero D; Gaillard ME; Fingermann M; Graieb A; Rumbo M; Hozbor D
    Vaccine; 2008 Aug; 26(36):4639-46. PubMed ID: 18640169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and protective efficacy of a recombinant filamentous haemagglutinin from Bordetella pertussis.
    Knight JB; Huang YY; Halperin SA; Anderson R; Morris A; Macmillan A; Jones T; Burt DS; Van Nest G; Lee SF
    Clin Exp Immunol; 2006 Jun; 144(3):543-51. PubMed ID: 16734625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous determination of Bordetella pertussis toxin and filamentous haemagglutinin concentrations by hydroxyapatite high-performance liquid chromatography.
    Chong P; Jackson G; Cwyk W; Klein M
    J Chromatogr; 1990 Jul; 512():227-36. PubMed ID: 2172264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group.
    Greco D; Salmaso S; Mastrantonio P; Giuliano M; Tozzi AE; Anemona A; Ciofi degli Atti ML; Giammanco A; Panei P; Blackwelder WC; Klein DL; Wassilak SG
    N Engl J Med; 1996 Feb; 334(6):341-8. PubMed ID: 8538704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective immunogenicity of synthetic peptides selected from the amino acid sequence of Bordetella pertussis toxin subunit S1.
    Askelöf P; Rodmalm K; Wrangsell G; Larsson U; Svenson SB; Cowell JL; Undén A; Bartfai T
    Dev Biol Stand; 1991; 73():111-20. PubMed ID: 1778305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Production of a safe, potent and immunogenic partially purified acellular pertussis vaccine using simple indigenous techniques.
    Gupta RK; Saxena SN; Sharma SB; Ahuja S
    Dev Biol Stand; 1991; 73():205-22. PubMed ID: 1778314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acellular Bordetella pertussis vaccine enhances mucosal interleukin-10 production, induces apoptosis of activated Th1 cells and attenuates colitis in Galphai2-deficient mice.
    Ohman L; Willén R; Hultgren OH; Hultgren Hörnquist E
    Clin Exp Immunol; 2005 Jul; 141(1):37-46. PubMed ID: 15958068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel configurations of high molecular weight species of the pertussis toxin vaccine component.
    Fowler S; Byron O; Jumel K; Xing D; Corbel MJ; Bolgiano B
    Vaccine; 2003 Jun; 21(19-20):2678-88. PubMed ID: 12744905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of 13 acellular pertussis vaccines: overview and serologic response.
    Edwards KM; Meade BD; Decker MD; Reed GF; Rennels MB; Steinhoff MC; Anderson EL; Englund JA; Pichichero ME; Deloria MA
    Pediatrics; 1995 Sep; 96(3 Pt 2):548-57. PubMed ID: 7659475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acellular pertussis vaccines: neutralization by immune sera of the lethality of pertussis toxin and viable Bordetella pertussis for chick embryos.
    Calver GA
    Biologicals; 1999 Jun; 27(2):143-7. PubMed ID: 10600203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of acellular pertussis vaccines-induced immunity against infection due to Bordetella pertussis variant isolates in a mouse model.
    Denoël P; Godfroid F; Guiso N; Hallander H; Poolman J
    Vaccine; 2005 Nov; 23(46-47):5333-41. PubMed ID: 16054273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detoxification of pertussis toxin by site-directed mutagenesis: a review of connaught strategy to develop a recombinant pertussis vaccine.
    Loosmore S; Cockle S; Zealey G; Boux H; Phillips K; Fahim R; Klein M
    Mol Immunol; 1991 Mar; 28(3):235-8. PubMed ID: 1708104
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.